2012-09-18 08:10:16 - Fast Market Research recommends "Down Syndrome - Pipeline Review, H2 2012" from Global Markets Direct, now available

Global Markets Direct's, 'Down Syndrome - Pipeline Review, H2 2012', provides an overview of the Down Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Down Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Down Syndrome. 'Down Syndrome - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/463815_down_syndrome_pipeline_review_h2_2012 ..


Note*: Certain sections in the report may be removed or altered based on the availability

and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Down Syndrome.
* A review of the Down Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Down Syndrome pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Down Syndrome.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Down Syndrome pipeline depth and focus of Down Syndrome therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Down Syndrome Therapeutic Products under Development, Key Players in Down Syndrome Therapeutics, Down Syndrome Pipeline Overview, Down Syndrome Pipeline, Down Syndrome Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Down Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Down Syndrome
Down Syndrome Therapeutics under Development by Companies
Down Syndrome Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Down Syndrome Therapeutics - Products under Development by Companies
Down Syndrome Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Down Syndrome Therapeutics Development
F. Hoffmann-La Roche Ltd.
AC Immune SA
NeuroNascent, Inc.
Down Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACI-24 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NNI-351 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG-1662 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liq-Nol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rivastigmine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Down Syndrome Therapeutics - Drug Profile Updates
Down Syndrome Therapeutics - Discontinued Products
Down Syndrome Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Down Syndrome, H2 2012
Products under Development for Down Syndrome - Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463815&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.